
    
      The primary objective of this study is to evaluate the long-term safety and tolerability of
      multiple intravenous (IV) doses of sifalimumab in adult participants with active SLE or DM or
      PM who were previously treated with investigational product (sifalimumab or placebo) in one
      of the following sifalimumab clinical studies: MI-CP151, MI-CP152, or MI-CP179.
    
  